23andMe (ME) Competitors $3.27 +0.21 (+6.86%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ME vs. BTMD, NGNE, VYGR, CTNM, SLRN, KMDA, TRVI, ETON, CGC, and AQSTShould you be buying 23andMe stock or one of its competitors? The main competitors of 23andMe include biote (BTMD), Neurogene (NGNE), Voyager Therapeutics (VYGR), Contineum Therapeutics (CTNM), Acelyrin (SLRN), Kamada (KMDA), Trevi Therapeutics (TRVI), Eton Pharmaceuticals (ETON), Canopy Growth (CGC), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical products" industry. 23andMe vs. biote Neurogene Voyager Therapeutics Contineum Therapeutics Acelyrin Kamada Trevi Therapeutics Eton Pharmaceuticals Canopy Growth Aquestive Therapeutics biote (NASDAQ:BTMD) and 23andMe (NASDAQ:ME) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk. Do analysts prefer BTMD or ME? biote presently has a consensus price target of $9.11, suggesting a potential upside of 49.34%. 23andMe has a consensus price target of $9.40, suggesting a potential upside of 187.46%. Given 23andMe's higher possible upside, analysts plainly believe 23andMe is more favorable than biote.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score biote 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.0023andMe 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Is BTMD or ME more profitable? biote has a net margin of 5.20% compared to 23andMe's net margin of -318.39%. biote's return on equity of -32.41% beat 23andMe's return on equity.Company Net Margins Return on Equity Return on Assets biote5.20% -32.41% 22.26% 23andMe -318.39%-129.98%-62.37% Do insiders and institutionals have more ownership in BTMD or ME? 21.7% of biote shares are held by institutional investors. Comparatively, 36.1% of 23andMe shares are held by institutional investors. 13.9% of biote shares are held by insiders. Comparatively, 26.3% of 23andMe shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community prefer BTMD or ME? biote received 2 more outperform votes than 23andMe when rated by MarketBeat users. Likewise, 100.00% of users gave biote an outperform vote while only 60.00% of users gave 23andMe an outperform vote. CompanyUnderperformOutperformbioteOutperform Votes14100.00% Underperform VotesNo Votes23andMeOutperform Votes1260.00% Underperform Votes840.00% Which has better earnings and valuation, BTMD or ME? biote has higher earnings, but lower revenue than 23andMe. 23andMe is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratiobiote$193.06M1.72$3.32M$0.2623.4623andMe$193.26M0.44-$666.70M-$25.32-0.13 Does the media favor BTMD or ME? In the previous week, biote had 3 more articles in the media than 23andMe. MarketBeat recorded 5 mentions for biote and 2 mentions for 23andMe. 23andMe's average media sentiment score of 1.14 beat biote's score of 0.79 indicating that 23andMe is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment biote 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 23andMe 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, BTMD or ME? biote has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, 23andMe has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Summarybiote beats 23andMe on 12 of the 18 factors compared between the two stocks. Ad ProsperityPubThis Indicator called BOTH NVDA ralliesRarely would I label something as “the best” But in this rare instance, I believe this is THE BEST indicator for trading Nvida’s stock. Except, it’s not another tech stock like Nvidia. But rather a stock hiding in broad daylight… So, if you’d like to see what this stock is… Click this link here. Get 23andMe News Delivered to You Automatically Sign up to receive the latest news and ratings for ME and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ME vs. The Competition Export to ExcelMetric23andMePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.41M$6.57B$5.12B$9.07BDividend YieldN/A2.98%4.91%4.22%P/E Ratio-0.1310.5991.3417.19Price / Sales0.44195.381,116.59116.80Price / Cash1.1357.1642.6437.86Price / Book0.435.104.794.78Net Income-$666.70M$151.51M$120.07M$225.60M7 Day Performance-2.39%-2.15%-1.89%-1.24%1 Month Performance1.24%-3.14%11.45%3.36%1 Year Performance-80.81%11.50%30.61%16.58% 23andMe Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ME23andMe2.3629 of 5 stars$3.27+6.9%$9.40+187.5%-81.5%$85.41M$193.26M-0.13770Positive NewsBTMDbiote3.0893 of 5 stars$6.60+3.6%$9.11+38.0%+20.8%$358.62M$193.06M24.77194Positive NewsGap UpNGNENeurogene3.7337 of 5 stars$24.03+2.2%$60.83+153.2%N/A$356.97M$925,000.000.0090VYGRVoyager Therapeutics4.6114 of 5 stars$6.50+3.7%$17.00+161.5%-27.6%$355.10M$250.01M8.83100CTNMContineum Therapeutics1.9558 of 5 stars$13.56-3.3%$29.25+115.7%N/A$349.58M$50M0.0031News CoverageSLRNAcelyrin2.7884 of 5 stars$3.42+5.9%$11.75+243.6%-55.8%$343.13MN/A-1.31135KMDAKamada3.8909 of 5 stars$5.84-0.5%$14.50+148.3%-1.2%$335.68M$158.38M20.96360Positive NewsTRVITrevi Therapeutics3.0363 of 5 stars$4.34+4.1%$9.31+114.6%+214.0%$333.62MN/A-10.2020Gap DownHigh Trading VolumeETONEton Pharmaceuticals2.1328 of 5 stars$12.91+4.5%$15.00+16.2%+176.9%$333.59M$31.64M-56.1420CGCCanopy Growth2.4368 of 5 stars$3.05-1.9%$3.50+14.8%-41.0%$332.27M$220.27M-0.631,029Analyst RevisionNews CoverageAQSTAquestive Therapeutics1.495 of 5 stars$3.61flat$9.80+171.5%+95.2%$329.16M$50.58M-8.02160Analyst ForecastAnalyst RevisionNews CoveragePositive News Related Companies and Tools Related Companies BTMD Competitors NGNE Competitors VYGR Competitors CTNM Competitors SLRN Competitors KMDA Competitors TRVI Competitors ETON Competitors CGC Competitors AQST Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ME) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 23andMe Holding Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share 23andMe With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
